Ambrx Biopharma Inc. (AMAM) |
|
14.715 0.305 (2.12%)
|
06-09 13:14 |
|
Open: |
14.4 |
Pre. Close: |
14.41 |
|
High:
|
14.98 |
Low:
|
14.23 |
|
Volume:
|
162,451 |
Market Cap:
|
813(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 12:43:16 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 17.85 One year: 20.85 |
| Support: |
Support1: 12.52 Support2: 10.81 |
| Resistance: |
Resistance1: 15.28 Resistance2: 17.85 |
| Pivot: |
14.11 |
| Moving Average: |
MA(5): 13.81  MA(20): 13.86
MA(100): 8.52 MA(250): 4.47 |
| MACD: |
MACD(12,26): 0.7 Signal(9): 0.8 |
| Stochastic oscillator: |
%K(14,3): 71.2 %D(3): 57 |
| RSI: |
RSI(14): 60.4 |
| 52-week: |
High: 15.28 Low: 0.37 |
| Average Vol(K): |
3-Month: 551 (K) 10-Days: 455 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AMAM ] has closed below upper band by 25.5%. Bollinger Bands are 33.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
14.74 - 14.8 |
14.8 - 14.87 |
|
Low:
|
13.2 - 13.25 |
13.25 - 13.32 |
|
Close:
|
14.3 - 14.39 |
14.39 - 14.51 |
|
Company Description |
|
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California. |
Headline News |
Tue, 06 Jun 2023
Wall Street analysts' outlook for Ambrx Biopharma Inc. (AMAM) - SETE News
Mon, 05 Jun 2023
2023-06-05 | NDAQ:AMAM | Press Release | Ambrx Biopharma Inc. - Stockhouse Publishing
Fri, 02 Jun 2023
Oppenheimer Initiates Coverage of Ambrx Biopharma Inc - ADR ... - Nasdaq
Tue, 30 May 2023
Ambrx to Present at Multiple Upcoming Investor Meetings - GlobeNewswire
Fri, 26 May 2023
Should You Add Ambrx Biopharma Inc - ADR (AMAM) Stock to Your Portfolio Friday? - InvestorsObserver
Fri, 19 May 2023
Cantor Fitzgerald Initiates Coverage of Ambrx Biopharma Inc - ADR ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
55 (M) |
| Shares Float |
9 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
94 (%) |
|
Shares Short
|
769 (K) |
|
Shares Short P.Month
|
764 (K) |
Stock Financials |
|
EPS
|
-1.79 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.3 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-954 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
-38 |
|
Qtrly Rev. Growth
|
-98.5 |
|
Gross Profit (p.s.)
|
0.13 |
|
Sales Per Share
|
0.1 |
|
EBITDA (p.s.)
|
-0.99 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-56 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-8.27 |
|
PEG Ratio
|
-2.4 |
|
Price to Book value
|
4.46 |
|
Price to Sales
|
140.59 |
|
Price to Cash Flow
|
-14.6 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
